论文部分内容阅读
目的观察贝伐单抗联合化疗治疗晚期结直肠癌的近期疗效和不良反应。方法回顾性分析42例晚期结直肠癌患者化疗联合贝伐单抗治疗的临床资料,使用贝伐单抗(安维汀)联合氟尿嘧啶加奥沙利铂(FOLFOX4)或氟尿嘧啶加伊立替康(FOLFIRI)方案治疗,化疗应用4-6个周期,贝伐单抗应用直至病情进展。治疗过程中根据美国国立癌症研究所(NCI)制定的通用毒性评价标准(CTC)3.0版进行评价不良反应级别。结果 42例患者中,CR 1例,PR 18例,SD 8例,PD15例,有效率45.2%,疾病控制率64.3%。主要不良反应42例,患者发生3级血栓栓塞1例,较常见不良反应为1或2级的鼻出血、咯血、高血压、蛋白尿等,程度均较轻可以耐受。结论贝伐单抗联合FOLFOX4或FOLFIRI方案治疗晚期结直肠癌近期疗效好,其毒副反应患者可耐受,远期疗效有待进一步的研究。
Objective To observe the short-term curative effect and adverse reaction of bevacizumab combined with chemotherapy in the treatment of advanced colorectal cancer. Methods The clinical data of 42 patients with advanced colorectal cancer treated by chemotherapy combined with bevacizumab were retrospectively analyzed. Bevacizumab combined with Fluorouracil plus oxaliplatin (FOLFOX4) or fluorouracil plus irinotecan (FOLFIRI) ) Regimen, 4-6 cycles of chemotherapy and bevacizumab until disease progression. The course of treatment was assessed according to the Universal Toxicity Evaluation Criteria (CTC) version 3.0 developed by the National Cancer Institute (NCI). Results Among the 42 patients, CR was 1, PR 18, SD 8 and PD 15, the effective rate was 45.2% and the disease control rate was 64.3%. The main adverse reactions in 42 cases, patients with grade 3 thromboembolism in 1 case, the more common adverse reactions as grade 1 or 2 of epistaxis, hemoptysis, hypertension, proteinuria, to a lesser degree can be tolerated. Conclusion Bevacizumab combined with FOLFOX4 or FOLFIRI regimen in the treatment of advanced colorectal cancer has a good short-term curative effect, and its toxic side effects are tolerable. Long-term curative effect remains to be further studied.